Compare CCCC & NNOX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CCCC | NNOX |
|---|---|---|
| Founded | 2015 | 2011 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical Electronics |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 185.1M | 155.6M |
| IPO Year | 2020 | 2019 |
| Metric | CCCC | NNOX |
|---|---|---|
| Price | $2.96 | $1.74 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 1 |
| Target Price | ★ $12.20 | $5.00 |
| AVG Volume (30 Days) | ★ 2.8M | 2.0M |
| Earning Date | 05-06-2026 | 04-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 16.45 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $35,947,000.00 | N/A |
| Revenue This Year | N/A | $147.55 |
| Revenue Next Year | N/A | $81.13 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 1.02 | N/A |
| 52 Week Low | $1.21 | $1.66 |
| 52 Week High | $3.82 | $5.72 |
| Indicator | CCCC | NNOX |
|---|---|---|
| Relative Strength Index (RSI) | 53.88 | 36.61 |
| Support Level | $2.34 | $1.66 |
| Resistance Level | $3.20 | $3.09 |
| Average True Range (ATR) | 0.24 | 0.13 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 63.97 | 13.39 |
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients' lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. Its degrader medicines are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT1946, and CFT8919.
Nano X Imaging Ltd is engaged in the business of manufacturing medical imaging systems. It offers a Nanox System which is a combination of hardware and software. It develops a prototype of the Nanox.ARC, a medical imaging system incorporating its novel digital X-ray source; and Nanox.CLOUD, a companion cloud-based software that will allow for the delivery of medical screening as a service. It has three business segments: Nanox.ARC division, the radiology services division and the AI solutions division. Key revenue is generated from Radiology Services.